International Clinical Psychopharmacology最新文献_第5页

Dropped-Head syndrome: a possible new variant of clozapine-induced inflammation during titration. 低垂头综合征：氯氮平在滴定过程中引起炎症的一种可能的新变体。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000507

Paula Jhoana Escobedo-Aedo, Irene Pans, Enrique Baca-García, Jose de Leon, María-Luisa Barrigón, Santiago Ovejero

引用次数: 0

Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report. 病例报告：一名耐药抑郁症患者使用埃司氯胺酮鼻内喷雾剂后出现的自发分离症状。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-01-22 DOI: 10.1097/YIC.0000000000000527

Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin

{"title":"Differed spontaneous dissociative symptoms following the use of esketamine intranasal spray in a patient suffering from treatment-resistant depression: a case report.","authors":"Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin","doi":"10.1097/YIC.0000000000000527","DOIUrl":"10.1097/YIC.0000000000000527","url":null,"abstract":"Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted at a distance, often accompanied by anxiety. Delayed dissociative phenomena disappeared within the fourth week of treatment by esketamine. The literature mainly discusses dissociation during esketamine treatment sessions, with limited data on differed spontaneous episodes. Three hypotheses are discussed concerning the mechanism of occurrence of these dissociative phenomena, including esketamine's direct effect, central nervous system sensitization, and anxiety-induced dissociation. We present the first case of differed spontaneous dissociative effects after intranasal esketamine administration for treatment-resistant depression. Our main hypothesis suggests that esketamine may act as a 'pattern' for dissociative experiences, heightening the patient's ability to discern these phenomena during other instances of dissociation, such as acute anxiety attacks. Further research is needed to validate this hypothesis.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"37-40"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials. 卡利普嗪辅助治疗重度抑郁障碍的安全性和耐受性：2b期/3期临床试验的汇总分析。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000528

Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese

{"title":"Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials.","authors":"Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese","doi":"10.1097/YIC.0000000000000528","DOIUrl":"10.1097/YIC.0000000000000528","url":null,"abstract":"To characterize the safety and tolerability of adjunctive cariprazine in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT). Post hoc analyses evaluated pooled data from 2 fixed-dose phase 3 cariprazine studies (1.5 and 3 mg/d [approved doses for MDD]). In a separate safety analysis, cariprazine 0.1-4.5 mg/d was evaluated using data from the 2 fixed-dose trials plus 3 flexible-dose studies grouped by modal-daily dose. In the pooled phase 3 studies (placebo = 503, 1.5 mg/d = 502, 3 mg/d = 503), overall cariprazine-treated patients had high rates of study completion (90%). Patients had mostly mild/moderate treatment-emergent adverse events that caused premature discontinuation of 4.3%. Only akathisia, nausea, and insomnia occurred in ≥5% of cariprazine patients (any group) and at twice the rate of placebo; potential dose-dependent responses were observed for akathisia and insomnia. Cariprazine had a neutral metabolic profile, with mean weight increase of <1 kg. Modal-dose results were similar, and both analyses were consistent with the known safety profile of cariprazine across its approved indications. Adjunctive cariprazine therapy was safe and generally well tolerated in patients with MDD who had not obtained an adequate response to ADT monotherapy; no new safety signals were identified.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"27-36"},"PeriodicalIF":2.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding mood disorder treatments. 了解情绪障碍的治疗方法。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2025-01-01 Epub Date: 2024-11-27 DOI: 10.1097/YIC.0000000000000573

Alessandro Serretti

引用次数: 0

Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial. 番红花辅助利培酮治疗精神分裂症阴性症状：一项随机、双盲、安慰剂对照试验

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-12-12 DOI: 10.1097/YIC.0000000000000575

Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh

{"title":"Crocus sativus (saffron) adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled trial.","authors":"Siamand Mazhar, Ahmad Shamabadi, Kimia Kazemzadeh, Mohammad Aidin Farahvash, Atiye Heidari Dalfard, Bita Fallahpour, Mohammad-Reza Khodaei Ardakani, Shahin Akhondzadeh","doi":"10.1097/YIC.0000000000000575","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000575","url":null,"abstract":"Current treatments for schizophrenia encounter resistance, limited efficacy, and limiting complications, necessitating novel approaches. The effects of saffron on negative symptoms were investigated as it has shown neuroprotective and antipsychotic properties. Fifty-six clinically stable chronic schizophrenic outpatients were equally assigned to saffron 15 mg q12hr or placebo groups while continuing risperidone. The Positive and Negative Syndrome Scale (PANSS) was used to assess schizophrenia-related symptoms in weeks 4 and 8. Also, the patients were assessed for the Hamilton depression rating scale (HDRS) and adverse effects. The baseline characteristics of the groups were comparable (Ps > 0.05). There were significant time-treatment interaction effects on negative ( = 0.137), general psychopathology ( = 0.193), and total ( = 0.113) PANSS scores. Affirmatively, their reductions were significantly greater in the saffron group until weeks 4 (Cohen's ds = 0.922, 0.898, and 0.759, respectively) and 8 (Cohen's ds = 0.850, 1.047, and 0.705, respectively). Regarding the negative symptoms, a better 25% response rate was obtained in the saffron group until the endpoint (P = 0.003). The HDRS scores, extrapyramidal symptom rating scale scores, and side effect frequencies were comparable between the groups (Ps > 0.05). Saffron was beneficial for primary negative symptoms of chronic schizophrenia in a safe and tolerable manner. It also outperformed placebo in improving general psychopathology and total symptoms.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder. 非沉浸式与沉浸式虚拟现实之间的情感识别差异：精神分裂症和双相情感障碍的初步研究结果。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-12-06 DOI: 10.1097/YIC.0000000000000576

Mauro Scala, Daniel Sánchez-Reolid, Roberto Sánchez-Reolid, Patricia Fernández-Sotos, Verónica Romero-Ferreiro, Miguel Ángel Alvarez-Mon, Guillermo Lahera, Giuseppe Fanelli, Alessandro Serretti, Chiara Fabbri, Antonio Fernández-Caballero, Roberto Rodriguez-Jimenez

{"title":"Differences in emotion recognition between nonimmersive versus immersive virtual reality: preliminary findings in schizophrenia and bipolar disorder.","authors":"Mauro Scala, Daniel Sánchez-Reolid, Roberto Sánchez-Reolid, Patricia Fernández-Sotos, Verónica Romero-Ferreiro, Miguel Ángel Alvarez-Mon, Guillermo Lahera, Giuseppe Fanelli, Alessandro Serretti, Chiara Fabbri, Antonio Fernández-Caballero, Roberto Rodriguez-Jimenez","doi":"10.1097/YIC.0000000000000576","DOIUrl":"10.1097/YIC.0000000000000576","url":null,"abstract":"Deficits in social cognition may impair emotional processing and facial emotional recognition (FER) in patients with bipolar disorder (BD) and schizophrenia. FER is generally explored using photographs or images of static faces that do not fully capture the complexity of real-life facial stimuli. To overcome this limitation, we developed a set of dynamic virtual faces depicting six basic emotions (i.e. happiness, sadness, anger, fear, disgust, and surprise) and a neutral expression suitable for presentation in immersive and nonimmersive virtual realities. This study presents preliminary findings on the differences in FER accuracy from a frontal view between immersive and nonimmersive virtual realities among patients experiencing a relapse of schizophrenia ( n = 10), a manic phase of BD ( n = 10), and a group of healthy controls (HCs) ( n = 10). As a secondary objective, we compare the FER accuracy across these three groups. Patients with schizophrenia and BD showed similar accuracy in recognizing emotions in immersive and nonimmersive virtual reality settings. However, patients with schizophrenia exhibited lower FER accuracy than HCs in both settings. Individuals with BD showed intermediate accuracy between those with schizophrenia and HCs, although these differences were not statistically significant. Notably, recognition of negative emotions was significantly impaired in both groups of patients.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142785531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Catatonia as a debut of systemic lupus erythematosus: a case report on a diagnostic challenge. 作为系统性红斑狼疮首发症状的紧张症：诊断难题的病例报告。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-19 DOI: 10.1097/YIC.0000000000000572

Helena Andreu, Blanca Serra-Sarró, Laura Bueno, Òscar de Juan, Iñaki Ochandiano, Luis Olivier, Helena Álvarez, Ailin Herrero, Cecilia Mantellini, Miguel Vicente, Maria Sagué-Vilavella, Lidia Ilzarbe, Luis Pintor, Marina Garriga, Vicent Llorca-Bofí, Miquel Bioque

引用次数: 0

A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol. 文拉法辛和纳曲酮预防曲马多所致阿片类药物使用障碍患者复发的疗效比较研究。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2023-09-20 DOI: 10.1097/YIC.0000000000000487

Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly

{"title":"A comparative study of the efficacy of venlafaxine and naltrexone for relapse prevention in patients with opioid use disorder attributed to tramadol.","authors":"Medhat M Bassiony, Nelly R Abdelfattah, Amany Elshabrawy, Mary M Adly","doi":"10.1097/YIC.0000000000000487","DOIUrl":"10.1097/YIC.0000000000000487","url":null,"abstract":"Tramadol and venlafaxine share similar pharmacological characteristics that may allow for overlapping therapeutic indications for them. The objective of this study was to compare the efficacy of venlafaxine and naltrexone in the treatment of tramadol abuse. This comparative trial included 95 patients with tramadol abuse who were detoxified for 2 weeks. Twenty-eight participants underwent the maintenance phase, while the remaining participants (n = 67) dropped out. The patients were randomized to use 50 mg/day of naltrexone or 225 mg/day of venlafaxine for 8 weeks. All participants were interviewed using SCID-I (DSM-IV-TR) criteria for diagnosing substance use and other psychiatric disorders. The proportion of relapsed patients was comparable between the naltrexone and venlafaxine groups (29.4% vs. 30.4%, P = 0.9). However, participants in the venlafaxine group stayed in treatment longer than participants in the naltrexone group, and the difference was significant (22.9 ± 7.89 days vs. 16.9 ± 3.4 days, P = 0.01). Only psychiatric comorbidity was found to be significantly associated with retention in treatment (80% vs. 22%, P = 0.005). Venlafaxine is as effective as naltrexone in preventing relapse in patients with tramadol abuse. Venlafaxine was more effective than naltrexone in treatment retention.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"341-349"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41138050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients. 英国医用大麻登记处：分析医用大麻治疗广泛性焦虑症患者临床疗效的病例系列。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-02-02 DOI: 10.1097/YIC.0000000000000536

Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren

{"title":"UK Medical Cannabis Registry: a case series analyzing clinical outcomes of medical cannabis therapy for generalized anxiety disorder patients.","authors":"Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren","doi":"10.1097/YIC.0000000000000536","DOIUrl":"10.1097/YIC.0000000000000536","url":null,"abstract":"This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L. Adverse events were recorded using CTCAE version 4.0. A total of 120 patients were identified for inclusion, of which 38 (31.67%), 52 (43.33%), and 30 (25.00%) were prescribed oils, dried flower, and both formulations of CBMP. Associated improvements in GAD-7, SQS, and EQ-5D-5L at 1, 3, 6, and 12 months were observed compared to baseline ( P < 0.010). There were 24 (20.00%) patients who reported 442 (368.33%) adverse events, most of which were mild (n = 184, 41.63%) and moderate (n = 197, 44.57%). This study reports an association between initiation of a homogeneous CBMP therapy and improvements in anxiety severity and HRQoL in individuals with GAD. Moreover, therapy was well-tolerated at 12 months follow-up. Further investigation through randomized controlled trials will ultimately be required to determine causation.","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"350-360"},"PeriodicalIF":2.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424060/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139650706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venlafaxine for tramadol dependence and medical cannabis therapy for generalized anxiety disorder. 文拉法辛治疗曲马多依赖症和医用大麻治疗广泛性焦虑症。

IF 2.1 3区医学

International Clinical Psychopharmacology Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1097/YIC.0000000000000567

Alessandro Serretti

引用次数: 0